TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04804176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-low frequency repetitive transcranial magnetic stimulation
Description: Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-low frequency repetitive transcranial magnetic stimulation
Description: Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultra-low frequency repetitive transcranial magnetic stimulation
Description: Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
Study: NCT03912038

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention
Study: NCT01441973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Study: NCT03912740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Both groups will have remifentanil analgesia guided by the Nol-Index

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Both groups will have remifentanil analgesia guided by the Nol-Index
Study: NCT01093677

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution placebo BID for 14 days.
Study: NCT00978367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
Study: NCT01428375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (1) Paracetamol injection
Description: Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
Study: NCT01857089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotest CE
Description: Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement
Study: NCT01484600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN668: Injection Rate 1
Description: Subjects will receive REGN668 via SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN668: Injection Rate 2
Description: Subjects will receive study drug via alternate delivery (if necessary)
Study: NCT04590157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
Study: NCT01620918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: normal healing abutment
Description: Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nano-structured healing abutment
Description: Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
Study: NCT02207855

Intervention type: DRUG
Intervention: Chloroprocaine
Study: NCT02745353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxegol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxegol
Study: NCT02305277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)
Study: NCT01526408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famciclovir
Description: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
Study: NCT00994747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen (Flavor and Type of Infant Formula)
Description: Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen (Flavor and Type of Infant Formula)
Description: Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen (Flavor and Type of Infant Formula)
Description: Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen (Flavor and Type of Infant Formula)
Description: Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen (Flavor and Type of Infant Formula)
Description: Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil, milk-based formula
Description: Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
Study: NCT01702909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2
Study: NCT01124812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy
Description: Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~1. Cohorts 1, 2 \& 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 \& 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 \& 3. Treatment cycles will be repeated every 28 days.~2. Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~3. Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~   * Total treatment duration is 8-16 weeks
Study: NCT04158219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation for health and depression (BA-HD)
Description: Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
Study: NCT03828955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean peptides
Description: Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
Study: NCT03972215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Chloride
Description: Traditional Chinese Medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Berberine Chloride
Description: Traditional Chinese Medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study: NCT04401332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile health app
Description: asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
Study: NCT04743622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoprost
Description: preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: preserved latanoprost 1 drop once a day for 12 weeks to target eyes
Study: NCT02305277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)
Study: NCT02405598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 1. Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~2. VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)
Study: NCT02635893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 100 mg of Seromycin by mouth will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 100 mg of Seromycin by mouth will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 100 mg of Seromycin by mouth will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo pill will be administered instead of medication by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo pill will be administered instead of medication by mouth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: walking around a designated track at different speeds both forward and backward

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: walking around a designated track at different speeds both forward and backward

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation
Description: magnetic stimulation and electrical stimulation may be applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation
Description: magnetic stimulation and electrical stimulation may be applied
Study: NCT01265186

Intervention type: DEVICE
Intervention: Bispectral Index
Description: The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.

Intervention type: DEVICE
Intervention: Bispectral Index
Description: The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
Study: NCT02635893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation
Description: magnetic stimulation and electrical stimulation may be applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Stimulation
Description: this is a fake stimulation that is administered but will be unknow to the subject.
Study: NCT03193983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flaps Coverage
Description: Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusive Dressing
Description: Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
Study: NCT02144103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subtenon administration of autologous ADRC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study: NCT02090010

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique
Description: The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique
Description: The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
Study: NCT00223847

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Constraint Induced Language Therapy
Study: NCT01265186

Intervention type: DEVICE
Intervention: Amplitude-integrated EEG
Description: A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.

Intervention type: DEVICE
Intervention: Amplitude-integrated EEG
Description: A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
Study: NCT04301895

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuous conversational interaction
Description: Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
Study: NCT04277780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Sensor
Description: Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Management Instructions
Description: Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Management Instructions
Description: Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
Study: NCT01219712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colloids, dobutamin, levosimendan
Description: : The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Colloids, dobutamin, levosimendan
Description: : The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal
Study: NCT05718349

Intervention type: OTHER
Intervention: Biospecimen sampling
Description: From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.

Intervention type: OTHER
Intervention: Biospecimen sampling
Description: From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.

Intervention type: OTHER
Intervention: Biospecimen sampling
Description: From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.